HC Wainwright Issues Pessimistic Forecast for Repligen (NASDAQ:RGEN) Stock Price

Repligen (NASDAQ:RGEN) had its target price dropped by investment analysts at HC Wainwright from $240.00 to $180.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 7.89% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Finally, Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $184.73.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $166.84 on Thursday. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The firm’s 50-day simple moving average is $149.17 and its 200 day simple moving average is $145.43. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a market cap of $9.35 billion, a P/E ratio of -450.91, a P/E/G ratio of 4.51 and a beta of 0.97.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the previous year, the business earned $0.23 earnings per share. The company’s revenue was up 9.7% on a year-over-year basis. Equities analysts expect that Repligen will post 1.54 EPS for the current year.

Hedge Funds Weigh In On Repligen

Institutional investors have recently bought and sold shares of the stock. UMB Bank n.a. increased its stake in Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. grew its stake in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 127 shares in the last quarter. Resources Management Corp CT ADV purchased a new position in Repligen during the 3rd quarter valued at about $37,000. Quarry LP grew its stake in Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 239 shares in the last quarter. Finally, nVerses Capital LLC purchased a new position in Repligen during the 3rd quarter valued at about $45,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.